People In The News: Tracking The Latest Industry Personnel Moves
Executive Summary
deBethizy steps down as president and CEO at Targacept; new CEOs at Trophos and Cytheris; Dal Pan named permanent director of FDA Office of Surveillance and Epidemiology; more personnel announcements in this month’s column.
You may also be interested in...
Targacept, AstraZeneca Face Another Failure With NNR Class
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.